Why Global Top-Tier CDMOs’ ATT Departments Mandate the Establishment of High-Cost ‘Benchtop ATR-FTIR’ Infrastructure and a Comparative Analysis of Major Brands
The accuracy and speed of data in the highly regulated global biopharmaceutical manufacturing (CMO/CDMO) market represent both a corporate competitive advantage and the core of regulatory compliance. Driven by the recent patent expirations of global blockbuster drugs and the explosive growth of high-value modalities—such as monoclonal antibodies (mAbs), recombinant proteins, and Antibody-Drug Conjugates (ADCs)—pharmaceutical and … Read more